AllDocs -> cancers

Ovarian cancer detection by LAD 1 OVARIAN CANCER DETECTION BY LOGICAL ANALYSIS OF PROTEOMIC DATA Gabriela Alexe, RUTCOR, Rutgers Center for Operations Research, Rutgers University, Piscataway, NJ Sorin Alexe, RUTCOR, Rutgers Center for Operations Research, Rutgers University, Piscataway, NJ Lance A. Liotta, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD Emanuel Petricoin, Food and Drug Administration/National Institutes of Health, Clinical Proteomics Program, Department of Therapeutic Proteins/Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD Michael Reiss, University of Medicine and Dentistry of New Jersey, and Robert Wood Johnson Medical School, Dept. of Medicine, The Cancer Institute of New Jersey, New Brunswick, NJ Peter L. Hammer, RUTCOR, Rutgers Center for Operations ...

Ovarian Cancer Trials at RPCI Two new ovarian cancer prevention trials are accruing patients at RPCI. Initally, women in the Gilda Radner Familial Ovarian Cancer Registry were invited to participate, but any woman with an increased risk of ovarian cancer (either due to family history or previous use of fertility medication) may be eligible. Your patients may contact 1-877-ASK-RPCI (1-877- 275-7724) for more information. The first is a chemoprevention trial offered through the Gynecologic Oncology Group (GOG). It involves the use of a potential ovarian cancer preventive drug called fenretinide. Preliminary data indicate that fenretinide may delay or perhaps prevent the onset of ovarian cancer . The trial is open to women with a family history of ovarian cancer who are considering having their ovaries removed as a means to lower their ...

IM862 Clinical Trial For Ovarian Cancer RPCI is participating in a national multi-center, phase II clinical trial to evaluate the safety and effectiveness of combining standard initial chemotherapy (paclitaxel and carboplatin) with IM862 to treat ovarian cancer . Shashikant Lele, MD, Chairman of the Division of Gynecologic Oncology, Department of Surgery, RPCI, is the principal investigator of the study, which is sponsored by Cytran, Inc., of Seattle. Ovarian cancer patients may achieve clinical remission following surgery and standard chemotherapy. However, many patients relapse over time. IM862, is a synthesized version of a naturally-occurring peptide which may have anti- tumor effects. Pre-clinical research suggests that IM862 stimulates the immune system and inhibits the development of blood vessels (angiogenesis) needed by tumors to grow and metastasize. ...

MECHANISMS OF DISEASE 572 THE LANCET • Vol 359 • February 16, 2002 • www.thelancet.com Background New technologies for the detection of early- stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary. Methods Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary “training” set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non- cancer . The discovered pattern was then used to classify ...

Department of Defense Ovarian Cancer Research Program 2000 Awards Book September 2001 Headquarters, U.S. Army Medical Research and Materiel Command MCMR-PLF, 1077 Patchel Street Fort Detrick, Maryland 21702-5024 Page 2 i TABLE OF CONTENTS Introduction ..1 Fiscal Year 2000 Ovarian Cancer Research Program Funded Awards Ovarian Cancer New Investigator Awards .3 Program Project Awards ..4 Investigator-Initiated Research Project Award .4 Fiscal Year 2000 Ovarian Cancer Research Program Participants Peer Reviewers ..6 Integration Panel Members . .10 Ad Hoc Programmatic Reviewers . 11 Glossary of Terms ..13 Page 3 ...

Introduction xxvii C a n c e r S e r v i c e s C o l l a b o r a t i v e S e r v i c e I m p r o v e m e n t G u i d e Ovarian cancer This guide outlines examples of improvements that have been made to the delivery of ovarian cancer services. A summary of the journey for ovarian cancer patients is shown in Figure 1, overleaf. Ovarian cancer has an estimated incidence rate of 20 per 100,000 women. The mortality rate is 15 per 100,000 women, and the total number of deaths in England and Wales is around 4,000 per annum. 1 In the majority of cases, the disease has progressed to a late stage by the time it is diagnosed, and prognosis after diagnosis of ovarian cancer is poorer than for other gynaecological cancers. It has a relatively low frequency in comparison with some cancers; there is only one new case of ovarian cancer ...

Genetics in Primary Care: A Faculty Development Initiative Syllabus Material Breast and Ovarian Cancer Module: Page 1 Breast and Ovarian Cancer A resident asks. Why should a primary care doctor know about breast or ovarian cancer genetics? Key Points : Family history is an important tool in the assessment of breast and ovarian cancer risk Women are concerned about breast cancer and often over-estimate their risk. They may view themselves as candidates for genetic testing when their likelihood of a positive test is minimal. BRCA1/2 mutations are rare and there are few data to assess the outcome benefits of interventions to reduce risk Testing for BRCA1/2 is mentioned frequently in the medical and lay press. Your patient may ask you about the availability of gene testing for breast cancer Learning Objectives for the Breast Cancer ...

Ovarian cancer is the sixth most c o m m on cancer of women in the UK, yet it is the fo u rth most c o m m on site for fatal malignant disease in the female, after breast, c o l on and lung cancers ( w w w. s t at i s t i c s. go v. u k ) . One of the reasons for this d i s p r o p o rt i on is that most wo m e n present only when the disease has p r o gressed to an advanced stag e. Ovarian cancer typically produces v ag u e, gastrointestinal symptoms and this may partly explain its lat e p r e s e n t at i on. In the early stag e s there are rarely any specific s y m p t o m s. The most common f e atures are vague ga s t r o i n t e s t i n a l upset (usually dy s p epsia) or increasing abdominal girth, which is often ascribed to midd l e - ag e d s p r e a d . The cancer may be detected accidentally during a routine e x a m i n at ...

86 12. OVARIAN CANCER SCOPE OF THE PROBLEM Ovarian cancer is the seventh most common malignancy diagnosed in Connecticut women, accounting for 3.5 percent of invasive cancers. It is the leading cause of death from gynecological malignancies, accounting for about 5 percent of cancer deaths among Connecticut women or 200 deaths each year. Stage at Diagnosis and Relative Survival Rate Ovarian cancer has the worst prognosis of any gynecological cancer , because it produces no symptoms until it is at an advanced stage. In the United States, cancer incidence and survival rates are reported through the SEER program (see Appendix A). Between 1992 and 1997, 26 percent of ovarian cancers were localized at diagnosis, where the five-year relative survival rate was 95 percent, 10 percent had spread regionally by the time ...

stage at presentation. Staging is carried out surgically as ovarian cancers are found deep in the peritoneal cavity and staging cannot be carried out using currently available scanning techniques.There are a number of different types of ovarian cancers, of which epithelial tumours account for 90 per cent, and the different tumour types all require slightly different management. For this rea- son, this article will be limited to discussing the treatment of epithelial ovarian cancers. Sex cord/stromal tumours and germ cell tumours constitute the majority of non- epithelial cancers. It is impossible to discuss treatment of ovarian cancer without first defining the dif- ferent stages.The currently accepted staging from the International Federation of Gynae- cology and Obstetrics (FIGO) is shown in Table 1. O VERVIEW OF SURGERY A ...

J U L Y 1 9 9 9 • V O L . 6 1 9 2 • more frequently) and it is less common when the woman is on the contraceptive pill, which has a protective effect. The “average patient” presents with non- specific abdominal symptoms, such as distension and bloating. Three-quarters will have advanced disease, beyond the pelvis. Approximately 90 per cent of ovarian cancers are epithelial in origin.They may be divided into benign, borderline or malig- nant. The malignant epithelial tumours are the major cause of death and morbidity, and Special Feature By H. T H O M A S , FRCP, FRCR This month ovarian cancer is the topic of our special feature.This first article gives an overview of the possible causes, pathology and management of the disease.The second article details the treatment strategies ...

May 25, 2000 Addendum to the Fiscal Year 2000 (FY00) Ovarian Cancer Research Program (OCRP) Announcement This addendum has been provided to address questions about the Program Project Award mechanism. Program Project Awards are one of two funding mechanisms offered by the Department of Defense (DOD) OCRP for FY00. One of the goals of the Program Project Award mechanism is to enhance ovarian cancer research infrastructure. To extend infrastructure to a greater number of institutions, the OCRP Integration Panel (IP), consisting of experts from academic and non-DOD government institutions, has expressed a strong interest in recommending for funding those scientifically meritorious proposals from institutions that do not have active DOD or National Cancer Institute (NCI) program project-type grants for ovarian cancer research at the release date of the FY00 Program Announcement. ...

Department of Defense Ovarian Cancer Research Program 1999 Awards Book September 2000 Headquarters, U.S. Army Medical Research and Materiel Command MCMR-PLF, 1077 Patchel Street Fort Detrick, Maryland 21702-5024 Page 2 i TABLE OF CONTENTS Introduction..1 Fiscal Year 1999 Ovarian Cancer Research Program Funded Awards Idea Awards 5 New Investigator Awards.7 Fiscal Year 1999 Ovarian Cancer Research Program Participants Peer Reviewers11 Integration Panel Members ..15 Glossary of Terms ..19 Page 3 1 Introduction INTRODUCTION The U.S. Army Medical Research and Materiel Command is pleased to present the award list of funded projects for the fiscal year 1999 (FY99) Ovarian Cancer Research Program. ...

Ovarian Cancer What Is Cancer ? Cancer is a group of many related diseases. All forms of cancer involve out-of-control growth and spread of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, normal cells of most tissues divide only to replace worn-out or dying cells and to repair injuries. Cancer cells, however, continue to grow and divide, and can spread to other parts of the body. These cells accumulate and form tumors (lumps) that may compress, invade, and destroy normal tissue. If cells break away from such a tumor, they can travel through the bloodstream, or the lymph system to other areas of the body. There, they may settle and form "colony" tumors. In their new location, the cancer cells continue growing. The spread of a tumor ...

Medical Science Division 1 6 3 Drug Resistance in Model Systems. Hamilton, Ozols, Selvakumaran, Williams, Bao, Bingham, Schoenberger The aggressive therapy of ovarian cancer includes, as a cornerstone, cisplatin or one of its analogs. Thus, our investigations of the mechanisms of drug resistance in ovarian can- cer cells primarily involve the study of mecha- nisms of platinum resistance. One approach we have used to study this problem has been to produce cisplatin-resistant ovarian cancer cell lines by exposure of drug sensitive cell lines to increasing concentrations of cisplatin. The most resistant of these variants, C200, is nearly 500-fold resistant to cisplatin. These cell lines show a complex cross-resistance phenotype typical of clinical ovarian cancer ; they are cross-resistant to carboplatin, tetraplatin, melphalan, mitomycin ...

1 THE GENETICS OF BREAST AND OVARIAN CANCER I: A MODEL OF FAMILY HISTORY By A. S. Macdonald, H. R. Waters and C. T. Wekwete abstract We present a Markov model of breast cancer (BC) and ovarian cancer (OC) and estimate its transition intensities, mainly using United Kingdom population data. In the case of BC and OC, we estimate intensities according to BRCA1 and BRCA2 genotype. We use this to estimate the probabilities that an applicant for insurance has a BRCA1 or BRCA2 mutation, given complete or incomplete knowledge of her family history of BC and OC. Life (and other) insurance underwriters typically have incomplete knowledge of family history, for example no information on the number of healthy relatives. We show how these probabilities depend strongly on estimates of the mutation frequencies and penetrances, and conclude that it may not be appropriate to apply risk estimates based on ...

OVACOME FACTSHEET 14 The Staging of Ovarian Cancer What are the stages of Ovarian Cancer ? This factsheet explains the different stages of ovarian cancer and the reasons for this classification. Included are some comments about treatment for each stage. Cancer of the ovary spreads in two main ways. The most common is along the surface of the lining of the abdomen (the peritoneum) and bowel. Eventually the cancer spreads to involve the layer of fat inside the abdomen (the omentum) and the outside of the liver. The other frequent direction of spread is within the circulation of lymph fluid in the body which is important for immunity (the lymph system). The lymph from the ovaries goes initially to lymph nodes (glands) on the wall of the pelvis (pelvic lymph nodes) and then to lymph nodes around the aorta (para-aortic lymph nodes). ...

OVACOME FACTSHEET 24 Familial Ovarian Cancer The two genes involved in familial breast cancer (BRCA1 and 2) are also involved in familial ovarian cancer and many families are looking for information on the possibility of genetic testing for ovarian cancer . This factsheet summarises the present knowledge on genetic testing for ovarian and breast cancer , and looks at screening currently available for ovarian cancer when two or more relatives have developed ovarian or breast cancer . Can anyone have a genetic test to tell if they will develop ovarian cancer ? Most cancer genetic cancer centres offer testing to families with at least three people affected with ovarian or breast cancer . The two genes involved in ovarian and breast cancer , called BRCA1 and BRCA2, are long genes ...

OVACOME FACTSHEET 15 Is there a link between Ovarian Cancer and using talcum powder? Following publicity suggesting that women should not use talculm powder on the genital area owing to an increased risk of ovarian cancer , Ovacome asked Adam Rosenthal and Ian Jacobs to prepare a brief summary of the evidence in order to clarify the situation. Dr Adam Rosenthal is a research fellow in the Gynaecology Cancer Research Unit at Barts. Ian Jacobs is a Professor in Gynaecology and Director of the Gynaecology Cancer Research Unit at Barts. It could be that talc does not cause ovarian cancer , but that women who use talc are also exposed to another risk which we do not yet know about. w Case-control studies of this type can suffer from bias which can lead to inaccurate results. For example, women with ovarian cancer understandably seek a cause for ...

OVACOME FACTSHEET 13 The Role of Radiotherapy in Ovarian Cancer What is radiotherapy? Radiotherapy is the use of ionising radiation in the treatment of disease. As radiation passes through tissue it collides with atoms along its path. Energy is deposited and utilised by molecules to inflict damage to the DNA of a cell. If this damage is not repaired death of the cell may occur. Normal tissues usually have better repair mechanisms than tumour cells which allow them a better degree of protection. How is radiotherapy delivered? This can be done in two ways. External beam radiotherapy accounts for the majority of treatments given and is where radiation is produced from a machine and delivered to the target area from the outside, for example x-rays produced by a linear accelerator. Before treatment can be given a process of planning ...

OVACOME FACTSHEET 12 Ovarian Cancer and Your Sexuality As a Specialist Nurse supporting women of all ages who are living with a diagnosis of ovarian cancer , I am faced with the reality of the wider issues which potentially affect them. This factsheet covers the complex area of sexuality. Although this is important to all, it may be called into question suddenly and sometimes quite dramatically when a woman is living with the effects of ovarian cancer . Therefore it is an important area for discussion, but sadly, in my experience, it is often ignored. Women may find that they are not always given time or space to address how their sexuality is being affected; they are often too embarrassed to talk about it or bring it to the attention of healthcare professionals, and consequently may suffer in silence. Healthcare professionals, in turn, may ...

OVACOME FACTSHEET 19 Fertility Issues for Women with Ovarian Cancer As cancer treatments become more successful, the emphasis is hopefully shifting to include long- term quality of life issues for the woman and her family, rather than just focusing on survival. With this in mind, this factsheet covers the complex area of a woman’s fertility and the treatments commonly used to treat ovarian cancer which can affect fertility, sometimes permanently. In my experience as a Specialist Nurse supporting women of all ages undergoing treatment for ovarian cancer , the preservation of fertility appears to be one of the most important considerations for women of childbearing years. Even when a woman has not been planning or considering a pregnancy, or already has a child, when she is faced with the prospect of the cancer treatment threatening her ...

The Community Outreach Education Program of the Molecular Toxicology Center Presents: Breast and Ovarian Cancer : Genetic and Environmental Factors Special Guests: • Dr. Barbara Davis , Acting Chief, Laboratory of Women’s Health, National Institute of Environmental Health Sciences • Dr. Claire Bradley, Suffolk County Commissioner of Health • Lorraine Pace, Breast cancer educator and activist For More Information Contact: 631-444-2167 Come hear about the latest cutting edge research on the prevention and diagnosis of Breast & Ovarian Cancer ! Community Collaborators: • Suffolk County Department of Health • The Cancer Center of Stony Brook • The South Fork Breast Health Coalition • Cancer Survivors Center ...

1: Obstet Gynecol 1999 Mar;93(3):372-6 Perineal talc exposure and subsequent epithelial ovarian cancer : a case-control study. Wong C, Hempling RE, Piver MS, Natarajan N, Mettlin CJ Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. OBJECTIVE: To evaluate the role of talcum powder use as a risk factor for the development of epithelial ovarian cancer . METHODS: In a case-control study, 499 patients with epithelial ovarian cancer were frequency matched for age at diagnosis (-5 years) with a control population of 755 patients. The odds ratio (OR) for the development of epithelial ovarian cancer was estimated using logistic regression analysis with adjustment for age at diagnosis, parity, oral contraceptive use, smoking history, family history of epithelial ovarian cancer , age at menarche, menopausal status, income, ...

1: J Natl Cancer Inst 2000 Feb 2;92(3):249-52 Prospective study of talc use and ovarian cancer . Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, Hankinson SE Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Dorota.Gertig@channing.harvard.edu BACKGROUND: Perineal talc use has been associated with an increased risk of ovarian cancer in a number of case-control studies; however, this association remains controversial because of limited supporting biologic evidence and the potential for recall bias or selection bias in case- control studies. In this study, we conducted a prospective analysis of perineal talc use and the risk of ovarian cancer . METHODS: The Nurses' Health Study is a prospective study of 121 700 female registered nurses in the United States who were aged 30-55 years at enrollment ...

November 1999 Headquarters, U.S. Army Medical Research and Materiel Command MCMR-PLF, 524 Palacky Street Fort Detrick, Maryland 21702-5024 Department of Defense Ovarian Cancer Research Program 1998 Awards Book Page 2 INTRODUCTION The Department of Defense (DOD) and the U.S. Army Medical Research and Materiel Command is pleased to present the award list and abstracts of funded projects for the Fiscal Year 1998 (FY98) Ovarian Cancer Research Program. On September 30, 1999 award negotiations were completed. The awards listed in this document were selected by a competitive two-tiered review process. Funding decisions were based upon scientific excellence evaluated in the first tier of review followed by programmatic relevance judged in the second tier. These projects represent a diverse portfolio of scientific research directed ...

1 6 4 Medical Science Division THE BIOLOGY OF OVARIAN CANCER Thomas C. Hamilton, Ph.D., Senior Member; Adjunct Professor of Chemistry, Lehigh University Robert F. Ozols, M.D., Ph.D., Senior Member, Senior Vice President, Medical Science; Associate Dean, Temple University School of Medical Abbas Abdollahi, Ph.D., Staff Scientist Anne Petra Crijns, Ph.D., Visiting Scientist, University of Groningen, Netherlands Catherine A. Bingham, Ph.D., Research Associate Denise Connolly, Ph.D., Research Associate Muthu Selvakumaran, Ph.D., Research Associate Rudi Bao, M.D., Postdoctoral Fellow, World Health Organization Fellow, P.R. China Stephen J. Williams, Ph.D., Postdoctoral Associate David Roberts, M.S., Graduate Student, Lehigh University, Bethlehem, PA Jeremy ...

438 Annals of Saudi Medicine, Vol 19, No 5, 1999 OVARIAN CANCER RECURRENCE AT THE LAPAROSCOPIC PORT FOR CHOLECYSTECTOMY Saif S. Al-Sobhi, FRCS(Glasg); Hamza A. Shirah, MBBS; Jamal Subhi, MD ; Tarek Amin, FRCSC; Ahmad Martan, MD; Mashael Al Deery, MD Cancer recurrence at the laparoscopic ports is a well- known complication of laparoscopic surgery. The frequency of the complication is increasing in recent years because of the wide use and popularity of laparoscopic surgery. We report two cases of ovarian papillary carcinoma which recurred at the port of laparoscopic cholecystectomy. The tumor was localized at the portal site with no evidence of metastases at any other site. The patients had laparoscopic cholecystectomy for chole- lithiasis some time before the ...

Vol. 6, No. 6 February 18, 2000 Innovative ovarian cancer research spanning detection and treatment is taking place at USC/Norris Compre- hensive Cancer Center, thanks to seed money donated by the Los Angeles- based Lynne Cohen Foundation. The donations—to studies that have now shown enough promise to garner ma- jor federal funding—highlight the importance of private donations to the steady progress in cancer research. Started in 1998 by three young sis- ters in honor of their mother who had recently succumbed to ovarian cancer , the Lynne Cohen Foundation is dedi- cated to providing start-up funding for research that shows signs of increas- ing the survival rate for women with the disease. The funds are designed to act as a springboard to help physicians/scien- tists conduct pioneering ovarian can- cer research that might otherwise ...

Page 2 N EW D IRECTIONS IN Ovarian Cancer Research R EPORT OF THE S TRATEGIC P LANNING C ONFERENCE D ECEMBER 8–9, 1997 Sponsored by National Cancer Institute Society of Gynecologic Oncologists Public Health Service Office of Women’s Health Page 3 Executive Summary A n estimated 26,800 women were diagnosed with ovarian cancer in 1997, and an estimated 14,200 women died from ovarian cancer in 1997. The disease will affect approximately 25,400 additional women, and approximately 14,500 women will die from ovarian cancer in 1998. In addition, millions of women remain fearful and concerned about being diagnosed with this too often fatal disease. While early ...